Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic ...

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Oxford BioMedica PLC (OXBDF) reports an 18% revenue increase and significant progress in strategic initiatives for the first ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report). The ...

Discover how Oxford BioMedica's new patent enhances viral vector production efficiency with a novel nucleic acid sequence that regulates therapeutic protein translation.

Recent findings reveal that induced satellite cells can effectively regenerate muscle tissue, outperforming traditional ...

Oxford Biomedica plc ( OTCPK:OXBDF) Q2 2024 Earnings Conference Call September 23, 2024 8:00 AM ET Frank Mathias - Chief Executive Officer Sebastien Ribault - Chief Business Officer Lucinda Crabtree - ...

Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...

Proteomic analysis of tunneling nanotubes (TNTs) identifies CD9 and CD81 as major positive regulators of TNT formation.